Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec 1;117(48):30025-30026.
doi: 10.1073/pnas.2009253117. Epub 2020 Nov 12.

Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients

Chengliang Yang  1 , Elizabeth Liu  1 , Mingyao Liu  2   3
Affiliations
Comment

Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients

Chengliang Yang et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Comment in

Comment on

  • Effective treatment of severe COVID-19 patients with tocilizumab.
    Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Xu X, et al. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29. Proc Natl Acad Sci U S A. 2020. PMID: 32350134 Free PMC article.

References

    1. Xu X. et al. ., Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. U.S.A. 117, 10970–10975 (2020). - PMC - PubMed
    1. Alzghari S. K., Acuña V. S., Supportive treatment with tocilizumab for COVID-19: A systematic review. J. Clin. Virol. 127, 104380 (2020). - PMC - PubMed
    1. Sciascia S. et al. ., Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin. Exp. Rheumatol. 38, 529–532 (2020). - PubMed
    1. Roumier M., et al. , Interleukin-6 blockade for severe COVID-19. MedRxiv:10.1101/2020.04.20.20061861 (22 April 2020).
    1. Alattar R., et al. , Tocilizumab for the treatment of severe COVID-19. J. Med. Virol. 92, 2042−2049 (2020). - PMC - PubMed